About SynteractHCR
SynteractHCR is a Healthcare company based in Carlsbad (United States) founded in 1986, and was acquired by Amulet Capital Partners in May 2016. Full-service clinical CRO support is offered internationally across multiple phases. Its focus areas include Biopharma Outsourcing, CRO, Clinical Development and Full Service. Its competitors include Celgene, Syneos Health and Medelis WCCT Global; 2 of its 3 listed competitors have raised funding.
Company details
SynteractHCR, formed by the acquisition of Munich-based Harrison Clinical Research by San Diego-based Synteract in 2013, is a full-service international CRO supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. SynteractHCR has conducted Phase I-IV studies on six continents and 60 countries, offering expertise across multiple therapeutic areas, with a special focus in oncology, immunotherapy, CNS, infectious disease, endocrinology, cardiovascular and respiratory diseases, among other indications. SynteractHCR also has capabilities to offer customised services and rescue studies. SynteractHCR was acquired by Connecticut-based PE firm, Amulet Capital Partners in May 2016.
- Headquarters Carlsbad, United States
- Stage Acquired
- SectorsHealthcare
- Website synteracthcr.com
- Social LinkedIn X
- Acquired by Amulet Capital Partners (May 2016)
- Latest Funding Round$3M (USD), Unspecified
Feb 2014
- Investors
- Acquired byAmulet Capital Partners
(May 2016)
Funding Insights of SynteractHCR
- Total Rounds 1
- Last Round Unspecified — $3M
- First Round $3M
(Feb 2014)
All 1 funding rounds of SynteractHCR with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2014 | $3M | Unspecified | – | – | – |
1 investors in total: 1 institutional.
Investors in SynteractHCR
SynteractHCR has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Amulet Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Amulet Capital is focused on healthcare private equity investments. | amuletcapital.com | Greenwich, United States |
Investor details for SynteractHCR
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of SynteractHCR
3 dated milestones of SynteractHCR across 30 years, from founding to its latest funding, stage changes and deals.
- Founded SynteractHCR is founded.
- Funding First funding round of $3.0M.
- Exit Acquired by Amulet Capital Partners.
Competitors of SynteractHCR
SynteractHCR has 3 listed competitors in our database, 2 of them funded. They include Celgene, Syneos Health and Medelis WCCT Global.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| celgene.com | 1986 | Summit, United States | $45M | 4,891 | Therapies for cancer and inflammatory diseases are developed. | |
| syneoshealth.com | 1984 | Raleigh, United States | 29,395 | CRO clinical development services are provided by Syneos Health. | ||
| wcct.com | 1998 | Cypress, United States | $17M | 229 | Full-service CRO expertise in influenza and oncology research is offered. |
Detailed competitors of SynteractHCR
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of SynteractHCR
Websites that share an audience with SynteractHCR (synteracthcr.com).
Websites whose visitors overlap most with SynteractHCR. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| iconplc.com | 100% | 476.9K | #92,950 | View details | |
contractresearchmap.com | contractresearchmap.com | 93% | #1,800,021 | – | |
| advancedclinical.com | 92% | 19.1K | #1,685,216 | View details | |
| premier-research.com | 92% | 39.9K | #825,378 | View details | |
| covance.com | 91% | 20.2K | #688,229 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 18 similar websites and full traffic analytics for SynteractHCR
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 18 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as SynteractHCR (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about SynteractHCR
SynteractHCR was founded in 1986 and raised its 1st funding round 28 years after it was founded.
SynteractHCR is headquartered in Carlsbad, United States. It is registered at Carlsbad, California, United States.
SynteractHCR, formed by the acquisition of Munich-based Harrison Clinical Research by San Diego-based Synteract in 2013, is a full-service international CRO supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. SynteractHCR has conducted Phase I-IV studies on six continents and 60 countries, offering expertise across multiple therapeutic areas, with a special focus in oncology, immunotherapy, CNS, infectious disease, endocrinology, cardiovascular and respiratory diseases, among other indications. SynteractHCR also has capabilities to offer customised services and rescue studies. SynteractHCR was acquired by Connecticut-based PE firm, Amulet Capital Partners in May 2016.
SynteractHCR's top competitors include Syneos Health, Medelis WCCT Global and Celgene.
SynteractHCR has 1 investor. Key investors include Amulet Capital.
Yes. SynteractHCR was acquired by Amulet Capital Partners in May 2016.